Clover Enters into Agreement to Commercialise Quadrivalent Seasonal Influenza Vaccine
Monday, February 20, 2023
Clover Biopharmaceuticals announced that it entered into an exclusive agreement with Adimmune Corporation for Clover to distribute AdimFlu-S (QIS) in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older.
The agreement also grants Clover rights to commercialise AdimFlu-S (QIS) in Bangladesh, Brazil and the Philippines, contingent on regulatory approvals, and to potentially collaborate with Adimmune on the development of additional vaccine candidates including next-generation influenza vaccines.
Under the terms of the agreement, Clover gains commercial rights to AdimFlu-S (QIS) in mainland China, Bangladesh, Brazil and the Philippines. In the near term with commercial launch in H2 2023, Clover will be responsible for the distribution of AdimFlu-S (QIS) in mainland China, where the vaccine is already approved and where Clover can leverage its existing commercial infrastructure and growing sales organisation.
This partnership also brings Clover one step closer to establish a leading respiratory vaccine franchise, and allows to realise synergies with the ongoing commercialisation of the COVID-19 vaccine.
